Literature DB >> 15563814

[Cardiovascular risk of SCORE compared to Framingham. Consequences of the change proposed by the European Societies].

Antonio Maiques Galán1, Francisco Antón García, María Franch Taix, Xavier Albert Ros, Eugenia Aleixandre Martí, Angel Collado Gil.   

Abstract

BACKGROUND AND
OBJECTIVE: The European Societies in their last update introduce substantial changes to calculate the cardiovascular risk without thinking about the practical consequences. The objective was to evaluate the agreement between the charts of cardiovascular risk of second and the third recommendations of the European Societies to classify the patients of high risk and to analyze its differences. PATIENTS AND
METHOD: Patients (1,227) belonging to 3 primary care centres. Risk calculated to the 10 years by means of the equation of Framingham and SCORE for countries lowers risk. A risk of Framingham > or = 20% or SCORE > or = 5% defined the high risk.
RESULTS: The patients of high risk were 8.4% according to Framingham and 5.5% according to SCORE and the coefficient Kappa 0.718. 41.7% of the patients of high risk disagreed: high risk Framingham and SCORE not (40 patients, 88.9%) and high SCORE and Framingham not (5 patients, 11.1%). The group high risk Framingham and SCORE not 1 is constituted by 95% of males, age 60 years, cholesterol 246.2 mg/dl and 37.5% smokers.
CONCLUSIONS: The chart SCORE and Framingham have an acceptable agreement, but classify from high risk different percentage of population and with different characteristics. The use of the chart of the SCORE would exclude an important group of patients with Framingham high risk.

Entities:  

Mesh:

Year:  2004        PMID: 15563814     DOI: 10.1016/s0025-7753(04)75330-0

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  5 in total

1.  Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study.

Authors:  Francisco Buitrago; Juan Ignacio Calvo-Hueros; Lourdes Cañón-Barroso; Gerónimo Pozuelos-Estrada; Luis Molina-Martínez; Manuel Espigares-Arroyo; Juan Antonio Galán-González; Francisco J Lillo-Bravo
Journal:  Ann Fam Med       Date:  2011 Sep-Oct       Impact factor: 5.166

2.  Cost of poor adherence to anti-hypertensive therapy in five European countries.

Authors:  F S Mennini; A Marcellusi; J M Graf von der Schulenburg; A Gray; P Levy; P Sciattella; M Soro; G Staffiero; J Zeidler; A Maggioni; R E Schmieder
Journal:  Eur J Health Econ       Date:  2014-01-05

3.  Assessment of cardiovascular risk in Tunisia: applying the Framingham risk score to national survey data.

Authors:  O Saidi; D Malouche; M O'Flaherty; N Ben Mansour; H A Skhiri; H Ben Romdhane; L Bezdah
Journal:  BMJ Open       Date:  2016-11-30       Impact factor: 2.692

4.  Agreement between the SCORE and D'Agostino Scales for the classification of high cardiovascular risk in sedentary spanish patients.

Authors:  Manuel A Gómez-Marcos; Gonzalo Grandes; José A Iglesias-Valiente; Alvaro Sánchez; Imanol Montoya; Luis García-Ortiz
Journal:  Int J Environ Res Public Health       Date:  2009-11-11       Impact factor: 3.390

5.  Therapeutic implications of selecting the SCORE (European) versus the D'AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients.

Authors:  Manuel A Gómez-Marcos; Carlos Martínez-Salgado; Carlos Martin-Cantera; José I Recio-Rodríguez; Yolanda Castaño-Sánchez; Maria Giné-Garriga; Emiliano Rodriguez-Sanchez; Luis García-Ortiz
Journal:  BMC Cardiovasc Disord       Date:  2009-05-11       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.